Core Viewpoint - He Yuan Bio is set to become a new member of the Sci-Tech Innovation Board as it officially starts its issuance process, marking a significant step in the "1+6" reform of the Sci-Tech Board [2][4]. Group 1: Company Overview - Wuhan He Yuan Bio Technology Co., Ltd. is the first company to initiate the issuance process after the re-launch of the fifth set of standards for the Sci-Tech Board [6]. - He Yuan Bio has developed a globally pioneering "rice-derived hematopoietic" technology, which has received support from the national "Major New Drug Creation" program [6]. - The company's innovative drug, recombinant human albumin injection (from rice), was approved for market release by the National Medical Products Administration in July, aiming to reduce China's reliance on imported human serum albumin [6]. Group 2: Market Context - The issuance of He Yuan Bio is a reflection of the policy direction to enhance the adaptability and inclusiveness of the Sci-Tech Board for high-quality technology enterprises [6]. - Since the announcement of the "1+6" reform policy in June, the Sci-Tech Board has received 15 new IPO applications, including four from unprofitable companies [9]. - The Shanghai Stock Exchange has completed the technical system testing for the new registration of the Sci-Tech Growth Layer, with 5 million investors already authorized to trade in this layer [10]. Group 3: Issuance Details - He Yuan Bio is the first company to adopt differentiated lock-up and allocation arrangements for offline issuance, with a minimum lock-up ratio of 40% for offline investors [6]. - The company has set three tiers of differentiated lock-up levels for investor bids, with the highest lock-up tier having a distribution ratio at least nine times that of the lowest tier [6][7]. - The recent revision of the issuance and underwriting rules by the Shanghai Stock Exchange allows unprofitable companies to adopt agreed lock-up methods, encouraging professional institutions to play a larger role in new stock pricing [7].

Group 1 - The core point of the article is that Rendu Biotech announced the listing of its shares, which will be subject to a lock-up period and will be available for trading starting September 30, 2025 [1] - The type of stock listing is a first-time restricted share offering, with a total of 8,431,604 shares being listed [1] - The method of stock subscription is offline, indicating a specific approach to how investors can acquire these shares [1]

中国国际金融股份有限公司 关于上海仁度生物科技股份有限公司 首次公开发行部分限售股上市流通的核查意见 中国国际金融股份有限公司（以下简称"中金公司"或"保荐机构"）作为上海仁 度生物科技股份有限公司（以下简称"仁度生物"或"公司"）首次公开发行股票并在 科创板上市项目的保荐机构，根据《证券发行上市保荐业务管理办法》《上海证券交易 所科创板股票上市规则》《上海证券交易所上市公司自律监管指引第 11 号——持续督 导》等有关法律法规和规范性文件的要求，对仁度生物首次公开发行部分限售股解禁上 市流通事宜进行了核查，发表核查意见如下： 一、本次上市流通的限售股类型 经中国证券监督管理委员会于 2022 年 2 月 15 日出具的《关于同意上海仁度生物科 技股份有限公司首次公开发行股票注册的批复》（证监许可〔2022〕332 号）同意，公 司获准向社会公开发行人民币普通股（A 股）10,000,000 股，并于 2022 年 3 月 30 日在 上海证券交易所科创板挂牌上市。公司首次公开发行 A 股前总股本为 30,000,000 股， 首次公开发行 A 股后总股本为 40,000,000 股，其中有限售条件流通股为 ...

一、本次上市流通的限售股类型 经中国证券监督管理委员会于2022年2月15日出具的《关于同意上海仁度生物 科技股份有限公司首次公开发行股票注册的批复》（证监许可〔2022〕332号）同 意，公司获准向社会公开发行人民币普通股（A股）10,000,000股，并于2022年3 月30日在上海证券交易所科创板挂牌上市。公司首次公开发行A股前总股本为 30,000,000股，首次公开发行A股后总股本为40,000,000股，其中有限售条件流通股 为31,818,377股，占总股本比例为79.55%，无限售条件流通股为8,181,623股，占总 股本比例为20.45%。 本次上市流通的限售股为公司首次公开发行前股东持有的部分限售股，涉及 限售股股东数量为2名，限售期限为自公司股票上市之日起42个月，该部分限售股 股东对应的股份总数为8,431,604股，占公司股本总数的21.04%。现锁定期即将届 满，上述限售股将于2025年9月30日起上市流通。 证券代码：688193 证券简称：仁度生物 公告编号：2025-040 上海仁度生物科技股份有限公司 关于公司首次公开发行部分限售股上市流通的公告 本公司董事会及全体董事保 ...

中国国际金融股份有限公司 关于上海仁度生物科技股份有限公司 2025 年半年度持续督导跟踪报告 中国国际金融股份有限公司（以下简称"中金公司"或"保荐机构"）作为上海仁度 生物科技股份有限公司（以下简称"仁度生物"或"公司"）首次公开发行股票并在科创 板上市项目的保荐机构，根据《证券发行上市保荐业务管理办法》《上海证券交易所 科创板股票上市规则》《上海证券交易所上市公司自律监管指引第 11 号——持续督导》 等相关规定，负责仁度生物上市后的持续督导工作，并出具本持续督导半年度跟踪报 告，具体情况如下： | 序号 | 工作内容 | 持续督导情况 | | --- | --- | --- | | 1 | 建立健全并有效执行持续督导工作制度，并针对具体 的持续督导工作制定相应的工作计划 | 保荐机构已建立并有效执行了持 | | | | 续督导制度，并制定了相应的工 | | | | 作计划。 | | 2 | 根据中国证监会相关规定，在持续督导工作开始前， | 保荐机构已与公司签订《保荐协 | | | 与上市公司或相关当事人签署持续督导协议，明确双 | 议》，该协议明确了双方在持续 | | | 方在持续督导期间的权利义务 ...

Investment Rating - The report maintains an "Overweight" rating for the in vitro diagnostics (IVD) industry [7]. Core Views - The IVD industry is currently facing short-term performance pressure due to medical insurance cost control and centralized procurement of IVD reagents, but a turning point is anticipated as the industry adapts to these changes [4][57]. - The global IVD market is experiencing promising growth, and the domestic IVD industry is expected to recover in the long term as it has largely completed the process of localization [5][57]. Summary by Sections Industry Performance - The pharmaceutical and biological sector rose by 1.40%, while the IVD sector fell by 1.97% during the week [1][10]. - The IVD sector's current Price-to-Earnings (PE) ratio is 37.38X, with a Price-to-Book (PB) ratio of 1.89X [3][29]. Financial Results - In the first half of 2025, the IVD sector reported total revenue of 18.43 billion yuan, a year-on-year decline of 15.2%, and a net profit attributable to shareholders of 2.96 billion yuan, down 27.7% year-on-year [4][51]. - The revenue and net profit decline in Q2 2025 was more pronounced compared to Q1 2025 [4][53]. Investment Recommendations - The report suggests focusing on specific growth areas within the IVD sector, particularly in immunodiagnostics, chemiluminescence, molecular diagnostics (PCR), and continuous glucose monitoring (CGM) [5][57]. - Companies such as SanNuobiology, Shengxiang Biology, and Yahui Long are highlighted as key players to watch in these segments [5][57].

Core Insights - The company has achieved a breakthrough in research and development with the successful creation of a new technology platform called "Digital SAT + Fully Automated Equipment DigiNAT," which surpasses existing digital PCR technology in sensitivity, ease of use, and speed of detection [2] - The platform opens new pathways for precise RNA quantification detection and is expected to be applied in areas such as early cancer screening, infectious disease detection, and personalized medicine [2] - The company has initiated the development of RNA digital precision quantification detection products, focusing on urinary system tumor screening products for prostate cancer and bladder cancer [2] - The company is actively pursuing intellectual property protection around its core technology, with several domestic and international invention patents applied for, some of which have already been granted [2] - Additionally, the company's self-developed Chlamydia (CT) and Human Papillomavirus (HPV) testing reagents have successfully passed EU regulatory agency review and obtained IVDRCE certification, facilitating future international collaborations and expansion of overseas sales networks [2]

Core Insights - Shanghai Rendu Biotechnology Co., Ltd. has released a semi-annual evaluation report on its "Quality Improvement and Efficiency Enhancement Return" action plan, highlighting the successful development of a new technology platform called "Digital SAT + Fully Automated Equipment DigiNAT" [1] - The new platform demonstrates significant advantages in detection sensitivity, operational convenience, and detection speed compared to traditional digital PCR technology, offering a more efficient and precise RNA detection solution with broad application potential [1] - Rendu Biotechnology is advancing the application of the Digital SAT platform in urinary system tumor screening, particularly for prostate and bladder cancer urine tests, with notable research progress [1] - The company aims to leverage its technological advantages to penetrate the tumor screening field amid the ongoing global development of precision medicine and early screening technologies [1]

Core Viewpoint - RenDu Bio (688193) reported a decline in revenue and net profit for the first half of 2025, but is positioning itself for long-term growth through technological innovation and international expansion [1][2][3] Financial Performance - The company achieved operating revenue of 81.24 million yuan, a year-on-year decrease of 6.27% - The net profit attributable to shareholders was 2.038 million yuan, down 52.94% compared to the previous year [1] Product Development and Innovation - RenDu Bio focused on building new technology platforms and developing new product lines, successfully creating the "Digital SAT + Automatic Supporting Equipment DigiNAT" platform - This platform offers significant advantages over traditional digital PCR technology, including reduced DNA background interference and improved detection speed - The company is developing RNA digital quantitative detection products, particularly for cancer screening and diagnosis, with progress in prostate and bladder cancer tests [2] Market Opportunities - The global liquid biopsy market is expected to maintain a compound annual growth rate of over 20% in the next five years, with urine testing being one of the fastest-growing segments - The rising demand for early screening and diagnosis of high-incidence tumors like prostate and bladder cancer presents a significant opportunity for the company [2] International Expansion - RenDu Bio has made strides in international markets, signing contracts with users in the US, Japan, Indonesia, and Vietnam, and achieving its first sale in India - The company has also secured IVDR CE certification for its Chlamydia (CT) and Human Papillomavirus (HPV) testing reagents, enhancing its ability to enter the EU market [3] Regulatory and Competitive Landscape - The IVDR certification signifies the company's strong capabilities in product development and compliance, which is crucial in the highly regulated EU market - The successful certification of key products highlights the company's systematic advantages in research, clinical translation, and regulatory compliance, laying a solid foundation for future international registrations [3]

Core Viewpoint - The company, Rendu Biotech, reported a decline in revenue and net profit for the first half of 2025, but is focusing on technological innovation and international expansion to drive long-term growth [2][3][4]. Financial Performance - The company achieved operating revenue of 81.24 million yuan, a year-on-year decrease of 6.27% [2]. - The net profit attributable to shareholders was 2.038 million yuan, down 52.94% year-on-year [2]. - Despite challenges, the company saw over 50% year-on-year growth in sales of certain blood test products, particularly in the hepatitis B sector [2]. R&D and Innovation - The company has developed a new technology platform called "Digital SAT + Automatic Supporting Equipment DigiNAT," which offers significant advantages over traditional digital PCR technology [3]. - The company is focusing on RNA digital precision quantitative detection products, particularly in cancer screening and diagnosis, with ongoing development of prostate and bladder cancer tests [3]. - The global liquid biopsy market is expected to grow at a compound annual growth rate of over 20% in the next five years, with urine testing being one of the fastest-growing segments [3]. International Expansion - The company has made strides in international markets, signing contracts with users in the US, Japan, Indonesia, and Vietnam, and achieving its first sale in India [4]. - The company’s chlamydia (CT) and human papillomavirus (HPV) test kits received IVDR CE certification from a European Union notified body, allowing entry into the EU market [4]. - The certification highlights the company's strengths in product development and regulatory compliance, positioning it well for future international registrations [4].